The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study

被引：0
|
作者：
Francesco Russo
Michele Linsalata
Caterina Clemente
Benedetta D’Attoma
Antonella Orlando
Giovanna Campanella
Francesco Giotta
Giuseppe Riezzo
机构：
[1] National Institute for Digestive Diseases I.R.C.C.S. “Saverio de Bellis”,Laboratory of Experimental Biochemistry
[2] Medical Oncology Unit I.R.C.C.S. “Saverio de Bellis”,Laboratory of Experimental Pathophysiology
[3] Castellana Grotte,undefined
[4] Medical Oncology Unit I.R.C.C.S. “Giovanni Paolo II”,undefined
[5] National Institute for Digestive Diseases I.R.C.C.S. “Saverio de Bellis”,undefined
[6] Castellana Grotte,undefined
来源：
BMC Cancer | / 13卷
关键词：
Breast cancer; Chemotherapy-induced diarrhea; Epidermal growth factor; Intestinal permeability; Ghrelin; Glucagon-like peptide 2; Gut peptides; Zonulin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] FEC (FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE) PLUS GRANULOCYTE MACROPHAGE-COLONY-STIMULATING FACTOR (GM-CSF) IN ADVANCED OR INFLAMMATORY BREAST-CANCER - A DOSE-FINDING STUDY
    LORUSSO, V
    TATULLI, C
    BERARDI, F
    BRANDI, M
    DEMITRIO, A
    CATALDI, A
    FIORETTO, A
    SARCINA, R
    SCHITTULLI, F
    DELENA, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1993, 3 (02) : 223 - 228
  • [22] Epirubicin Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil versus Paclitaxel Followed by Epirubicin and Vinorelbine in Patients with High-Risk Operable Breast Cancer
    Boccardo, Francesco
    Amadori, Dino
    Guglielmini, Pamela
    Sismondi, Piero
    Farris, Antonio
    Agostara, Biagio
    Gambi, Angelo
    Catalano, Giuseppina
    Faedi, Marina
    Rubagotti, Alessandra
    ONCOLOGY, 2010, 78 (3-4) : 274 - 281
  • [23] Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study
    Shizuku, Masato
    Shibata, Masahiro
    Shimizu, Yoshimi
    Takeuchi, Dai
    Mizuno, Yutaka
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2020, 82 (03): : 457 - 467
  • [24] Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
    Zhang, Minmin
    Wei, Wei
    Liu, Jianlun
    Yang, Huawei
    Jiang, Yi
    Tang, Wei
    Li, Qiuyun
    Liao, Xiaoming
    ONCOTARGETS AND THERAPY, 2016, 9 : 3443 - 3450
  • [25] Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients
    Lu Chen
    Huijie Qi
    Liudi Zhang
    Haixia Li
    Jie Shao
    Haifei Chen
    Mingkang Zhong
    Xiaojin Shi
    Ting Ye
    Qunyi Li
    BMC Cancer, 18
  • [26] Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel based chemotherapy in breast cancer patients
    Chen, Lu
    Qi, Huijie
    Zhang, Liudi
    Li, Haixia
    Shao, Jie
    Chen, Haifei
    Zhong, Mingkang
    Shi, Xiaojin
    Ye, Ting
    Li, Qunyi
    BMC CANCER, 2018, 18
  • [27] A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)
    Lindman, H.
    Andersson, M.
    Ahlgren, J.
    Balslev, E.
    Sverrisdottir, A.
    Holmberg, S. B.
    Bengtsson, N. O.
    Jacobsen, E. H.
    Jensen, A. B.
    Hansen, J.
    Tuxen, M. K.
    Malmberg, L.
    Villman, K.
    Anderson, H.
    Ejlertsen, B.
    Bergh, J.
    Blomqvist, C.
    EUROPEAN JOURNAL OF CANCER, 2018, 94 : 79 - 86
  • [28] Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients
    vanderWall, E
    Rutgers, EJT
    Holtkamp, MJ
    Baars, JW
    Schornagel, JH
    Peterse, JL
    Beijnen, JH
    Rodenhuis, S
    BRITISH JOURNAL OF CANCER, 1996, 73 (09) : 1080 - 1085
  • [29] A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer
    Yao, Xin
    Hosenpud, Janet
    Chitambar, Christopher R.
    Charlson, John
    Cheng, Yee Chung
    JOURNAL OF CANCER, 2012, 3 : 145 - 151
  • [30] Sequential dose-dense 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel in patients with early breast cancer with four or more positive lymph nodes
    Murialdo, Roberto
    Gallo, Maurizio
    Boy, Davide
    Zoppoli, Gabriele
    Tixi, Lucia
    Gonella, Roberta
    Ballestrero, Alberto
    Patrone, Franco
    TUMORI JOURNAL, 2014, 100 (02): : 128 - 135
12345